Science, medicine, and the future: Gene therapy

British Medical Journal

Volumn 315, Issue 7118, 1997, Pages 1289-1292

  Russell, Stephen J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; INTERFERON; MONOCLONAL ANTIBODY;

CELL DESTRUCTION; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC ENGINEERING; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SECRETION; SHORT SURVEY; SOMATIC CELL; TISSUE CULTURE;

EID: 0030714581     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.315.7118.1289     Document Type: Short Survey

References (17)

1. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan AA, Moen R, et al. Gene transfer into humans: immonotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
2. Vacanti CA, Mikos AG. Letter from the editors. Tissue Eng 1995;1:1-2.
3. Naffakh N, Henri A, Villeval JL, Rouyer-Fessard P, Moullier P, Blumenfeld N, et al. Sustained delivery of erythropoietin in mice by genetically modified skin tibroblasts. Proc Natl Acad Sci USA 1995;92:3194-8.
4. Moullier P, Bohl D, Heard J-M, Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin tibroblasts. Nat Genet 1993;4:154-9.
5. Bohl D, Heard J-M. Modulation of erythropoietin delivery from engineered muscles in mice. Hum Gene Ther 1997;8:195-204.
6. Evans CH, Mankin HJ, Fergason AB, Robbins PD, Ghivizzani SC, Herndon JH, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheuniatoid arthritis. Hum Gene Ther 1996;7:1261-80.
7. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol 1996;23:31-45.
8. Zhang J, Russell SJ. Vectors for cancer gene therapy, Semin Oncol 1996;15:385-401.
9. Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report, end 1996. Hum Gene Ther 1997;8:775-800.
10. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F. et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:199-209.
11. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Sievenson BJ, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Grue Ther 1997;4:210-18.
12. Blaese RM, Culver KW, Miller D, Carter CS, Fleisher T, Clerici M, et al I lymphocyte-directed gene therapy tnr ADA-SCID: initial trial results after 4 years. Science 1995;270:475-80.
13. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1907;276:1719-24.
14. Friedmann T. Overcoming the obstacles to gene therapy. Sci Am 1997;276:80-5.
15. Felgner P. Nonviral strategies for gene therapy. Sci Am 1997;276:86-91.
16. Cosset F-I., Russell SJ. Targeting retrovirus entry. Gene Ther 1996;3:946-56.
17. Haukins RF, Russell SJ, Marrus R, Ashworth LJ, Brissinck J, Zhang J, et al A pilot study of idiotypic vaccination follicular B-cell lyniphoma using a genetic approach. Hum Gene Ther 1997;81287-99.